Fig. 1: In vitro SLFN11 correlates with response to DDA and some DDRi. SLFN11 low or absent cancers are found across different tumour indications. | British Journal of Cancer

Fig. 1: In vitro SLFN11 correlates with response to DDA and some DDRi. SLFN11 low or absent cancers are found across different tumour indications.

From: SLFN11 informs on standard of care and novel treatments in a wide range of cancer models

Fig. 1

a Correlation of SLFN11 mRNA levels (RMA normalised gene expression) from 738 cell lines with the response to ~589 monotherapy anticancer therapeutics in a multidisciplinary effort from GDSC and AstraZeneca. GDSC genomics of drug sensitivity in cancer. The inset shows the 20 most significantly correlated compounds with SLFN11. b SLFN11 protein in Champions Oncology Patient-Derived Xenograft (PDX) models of the different cancer types as determined by IHC assay (N = 472). c SLFN11 RMA normalised gene expression in cell lines from GDSC grouped by tissue of origin. The bars represent medians ± s.d.

Back to article page